

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## UMP HEALTHCARE HOLDINGS LIMITED

### 聯合醫務集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 722)**

## **SUPPLEMENTAL ANNOUNCEMENT ON CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MEDICAL SERVICES AGREEMENT**

Reference is made to the announcement of UMP Healthcare Holdings Limited (the “**Company**”) dated 1 October 2022 (the “**Announcement**”) in relation to the Agreement and the transactions contemplated thereunder. Unless otherwise specified, capitalised terms used herein shall have the same meaning defined in the Announcement. This announcement is to provide further information on the pricing policy under the Agreement.

In determining the Service Fees under the Agreement, the Group will take into account the prevailing market prices and benchmark price information for similar services obtained through the market or third-party customers. Where comparable transactions are available, the business development department of the Group will consider the pricing for at least two transactions in which the Group provides substantially similar services to independent third-party customers during the relevant year, and report the findings, together with the recommended pricing determined based on such findings, to the senior management of the Group. The senior management will then review the recommended pricing to ensure that it complies with the pricing principle under the Agreement such that the price is no more favourable to FTLife than the price at which the Group provides similar services to other independent third parties. In the absence of any comparable transaction, the business development department of the Group will conduct market research (through means such as discussions with customers/market surveys) on the prevailing prices charged for similar services in the market in general, and report the findings, together with the recommended pricing determined based on such findings, to the senior management of the Group, which will then determine the prices for the relevant services.

The additional information disclosed herein does not affect any other information contained in the Announcement.

By Order of the Board  
**UMP Healthcare Holdings Limited**  
**SUN Yiu Kwong**  
*Chairman and Chief Executive Officer*

Hong Kong, 7 October 2022

*As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman and Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Managing Director), Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael, Mr. LEE Kar Chung, Felix and Dr. LEE Pak Cheung, Patrick; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Dr. LI Kwok Tung, Donald, Mr. YEUNG Wing Sun, Mike and Mr. CHAU, Chit Jeremy.*